PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK
Abstract
Authors
S. Webster N. Hau A.V. Ustyugova A.R. Kansal O. Reifsnider